Farmas USA

ACAD

Que rapido cambian de juego estos tios, y si lo buscas resulta que tiene su patrón.

5 min.

ACAD

Ataque.

Edito: nuevo artículo CNN

https://edition.cnn.com/2018/04/25/health/fda-nuplazid-safety-evaluation-invs/index.html

FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid

The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago.

"What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.

DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid.

"How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"

buenas ...

 framus tienes que poner orden GTC en vez de DAY.. entonces esa orden estara hasta que se cancele..

por cierto para hacienda de donde sacaste los datos de interactive brokers... mare que complicado tengo encontrar la mierda esta...

sdls

ACAD

Que cruz... No podían esperar un poco a que pudiera salir plano antes de soltar esa mierda de noticia...

ACAD

Yo entiendo que la FDA ya contestó la semana pasada. Lo que está claro es que hay alguien esforzándose mucho por tirarla: DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid.

Creo que promediaré en cualquier momento.

When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.
The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.

ACAD

Acaba de tocar los 16,33. Cuando abrió el otro día con la noticia lo hizo con 16,35. El mínimo fue 15,74. Igual empieza ahora el reversal. Si alguien quiere echarle unas rayicas serán bienvenidas.

ACAD

Como sea cierto que el producto no es seguro me da a mi que ni rayicas ni nada...

ACAD

Que no, que eso ya lo hablamos el otro día. No hay nada nuevo. Es más seguro que los de su clase y las muertes son sencillamente circunstanciales. Otra cosa es lo que quieran marear con el tema.